Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Phase 1 Completed 134 enrolled ModernaTX, Inc. AstraZeneca · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.

Timeline

Start: 2018-11-27
Primary completion: 2025-08-01
Completion: 2025-08-01

Publications

Srikrishna D, Sachsenmeier K. We need to bring R0 < 1 to treat cancer too. Genome Med. 2021 Jul 26;13(1):120. doi: 10.1186/s13073-021-00940-9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Durvalumab	Monoclonal antibody	—	Intravenous
Subject	mRNA-2752	Messenger RNA (mRNA)	—	Intrathecal

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Summary

Timeline

Publications

Drugs

Indications